A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma

Cancer

Volumn 113, Issue 11, 2008, Pages 3192-3198

  Pasricha, Sant Rayn ^a   Grigg, Andrew ^b   Catalano, John ^c   Leahy, Michael ^d   Underhill, Craig ^e   Arthur, Chris ^f   D'Rozario, James ^g   Lowenthal, Ray ^h   Reed, Kate ^a   Spencer, Andrew ^a  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c FRANKSTON HOSPITAL   (Australia)

^d FREMANTLE HOSPITAL   (Australia)

^e Border Medical Oncology Australia   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g CANBERRA HOSPITAL   (Australia)

^h ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Gemcitabine; Hodgkin lymphoma; Lymphoma; Non Hodgkin lymphoma; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; NAVELBINE; VINBLASTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; LYMPHOMA; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; RISK; SALVAGE THERAPY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; RISK; SALVAGE THERAPY; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 58149391068     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23915     Document Type: Article

References (28)

1. Davis DL, Hoel D, Fox J, Lopez A. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet. 1990;336:474-481. (Pubitemid 20264222)
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993;54:594-606. (Pubitemid 23188190)
3. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626.
4. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634.
5. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. N Engl J Med. 2003;348:2386.
6. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens the MD Anderson Cancer Center Experience. Hematol Oncol Clin North Am. 1997;11:937-947. (Pubitemid 27431154)
7. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma. N Engl J Med. 1995;333:1540.
8. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065-2071. (Pubitemid 34680969)
9. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol. 1992;10:210-218.
10. Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol. 2006;133:3-18. (Pubitemid 43328860)
11. Rule S, Tighe M, Davies S, Johnson S. Vinorelbine in the treatment of lymphoma. Hematol Oncol. 1998;16:101-105. (Pubitemid 29202168)
12. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of singleagent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma. 2004;5:110-115. (Pubitemid 39378321)
13. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet. 1996;31:184-197. (Pubitemid 26335905)
14. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23(5 suppl 10):3-15. (Pubitemid 26362189)
15. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3786.
16. Savage DG, Rule SAJ, Tighe M, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol. 2000;11:595.
17. Krajnik G, Mohn-Staudner A, Thaler J, et al. Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial. Ann Oncol. 2000;11:993-998.
18. Spencer A, Reed K, Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J. 2007;37:760-766.
19. Bartlett N, Niedzwiecki D, Johnson J, Friedberg JW, Zelenetz AD, Canellos GP. A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804 [abstract]. Proc Am Soc Clin Oncol. 2003;22. (Abstract 2275).
20. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997;17(5 Pt 2):146S-154S. (Pubitemid 27411255)
21. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007;92:35.
22. Weisdorf DJ, Andersen JW, Glick JH, Oken MM. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol. 1992;10:942.
23. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16:3264.
24. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Eur Soc Med Oncol. 2002;13:1264-1274. (Pubitemid 34960136)
25. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol. 1999;17:1244.
26. Miller AB, Hoogstraton B, Staquet M, Winkler A. WHO recommendations for grading of acute and subacute toxicity. Cancer. 1991;47:210-211.
27. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after 2 or 3 cycles of chemotherapy in Hodgkin lymphoma. Eur Soc Med Oncol. 2005;16:1160-1168. (Pubitemid 41418320)
28. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after 2 to 3 cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Eur Soc Med Oncol. 2005;16:1514-1523. (Pubitemid 41222425)